These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Listed as ongoing, but also has a completion date and reported results||2008-001551-22||A randomized, double-blind, placebo controlled, multicenter, phase II study of adding AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) to first li...||2014-11-07||bad-data|
|Listed as ongoing, but also has a completion date and reported results||2008-001552-44||A MULTICENTER OPEN LABEL PHASE II STUDY OF THE EFFICACY AND SAFETY OF AMG 479, A FULLY HUMAN MONOCLONAL ANTIBODY AGAINST INSULIN-LIKE GROWTH FACTOR TYPE 1 RECEPTOR (IGF-1R) AS SECOND LINE THERAPY IN P...||2013-05-23||bad-data|
|Listed as ongoing, but also has a completion date and reported results||2008-003175-45||A randomized phase II, open-label multicenter trial of panobinostat monotherapy in women with HER2 positive locally recurrent or metastatic breast cancer||2010-03-22||bad-data|
|Listed as ongoing, but also has a completion date and reported results||2008-003176-21||A phase II, open label multicenter trial of panobinostat (LBH589) monotherapy in women with HER2 negative locally recurrent or metastatic breast cancer||2015-04-02||bad-data|
|Completed, but no date, and reported results||2013-002192-18||A randomized open-label Phase II study of letrozole plus afatinib (BIBW2992) versus letrozole alone in first-line treatment of advanced ER+, HER2- postmenopausal breast cancer with low ER expression||bad-data|
|Reported results||2016-004151-79||A Presurgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist Darolutamide (ODM-201)||2019-03-28||due-trials|